Abstract
Bladder urothelial carcinoma (BC) has been identified as one of the most common malignant neoplasm worldwide. High-grade bladder urothelial carcinoma (HGBC) is aggressive with a high risk of recurrence, progression, metastasis, and poor prognosis. Therefore, HGBC clinical management is still a challenge. We performed the present study to seek new urine biomarkers for HGBC and investigate how they promote HGBC progression and thus affect the prognosis based on large-scale sequencing data. We identified the overlapped differentially expressed genes (DEGs) by combining GSE68020 and The Cancer Genome Atlas (TCGA) datasets. Subsequent receiver operating characteristic (ROC) curves, Kaplan-Meier (KM) curves, and Cox regression were conducted to test the diagnostic and prognostic role of the hub genes. Chi-square test and logistic regression were carried out to analyze the associations between clinicopathologic characteristics and the hub genes. Ultimately, we performed gene set enrichment analysis (GSEA), protein-protein interaction (PPI) networks, and Bayesian networks (BNs) to explore the underlying mechanisms by which ECM1, CRYAB, CGNL1, and GPX3 are involved in tumor progression. Immunohistochemistry based on The Human Protein Atlas and quantitative real-time polymerase chain reaction based on urine samples confirmed the downregulation and diagnostic values of the hub genes in HGBC. In conclusion, our study indicated that CRYAB, CGNL1, ECM1, and GPX3 are potential urine biomarkers of HGBC. These four novel urine biomarkers will have attractive applications to provide new diagnostic methods, prognostic predictors and treatment targets for HGBC, which could improve the prognosis of HGBC patients, if validated by further experiments and larger prospective clinical trials.
Highlights
Bladder urothelial carcinoma (BC) has been identified as the ninth most common malignant neoplasm all over the world [1, 2]
The results suggested that expressions of GPX3 (AUC = 0.8794, P = 0.0001), ECM1 (AUC = 0.9794, P < 0.0001), CRYAB (AUC = 0.9216, P < 0.0001), and CGNL1 (AUC = 0.9765, P < 0.0001) have good predictive power for diagnosis of high-grade bladder urothelial carcinoma (HGBC), indicating that they may be used as an urine biomarker for HGBC
The above findings could provide new diagnostic methods, prognostic predictor and treatment targets for HGBC, which could improve the prognosis of HGBC patients
Summary
Bladder urothelial carcinoma (BC) has been identified as the ninth most common malignant neoplasm all over the world [1, 2]. The age standardized incidence and number of deaths are decreasing in the past 20 years, the number of BC incident cases is growing globally and the BC burden may ascend in the future as a result of aged tendency of population and polluted environment [3, 4]. BC is classified as high-grade bladder urothelial carcinoma (HGBC) and low-grade bladder urothelial carcinoma (LGBC) based on how cancer cells histologically differ from normal bladder cells [5]. HGBC is aggressive and has a high risk of recurrence, progression, metastasis and poor prognosis, while LGBC is a kind of tumor with low malignancy and comparatively good prognosis [5]. HGBC patients should receive radical cystectomy with or without postoperative chemotherapy; LGBC patients are most commonly treated with transurethral resection of bladder tumor [6, 7]. An early and accurate diagnosis of BC, differential diagnosis between HGBC and LGBC, is a critical factor for clinical management of BC
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
